
- Telehealth Visits
- Insurance plan information

Afsaneh Amouzegar, MD
Hematology Oncology- Telehealth Visits
- Insurance plan information



Afsaneh Amouzegar, MD
Hematology Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Afsaneh Amouzegar is a medical oncologist who cares for patients with melanoma and non-melanoma skin cancers. She has a special interest in treating patients with rare subtypes of melanoma—such as acral and mucosal melanoma—and melanoma that has spread to the brain.
Amouzegar earned her medical degree at Tehran University of Medical Sciences. She completed a residency in internal medicine at the University of Pittsburgh Medical Center, followed by a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center. She also completed a postdoctoral research fellowship at the Schepens Eye Research Institute of Harvard Medical School.
Amouzegar's research focuses on understanding what makes rare forms of melanoma different from more common types. She is also passionate about improving care for patients with advanced melanoma with brain metastases, working on clinical trials and translational research projects to find better treatments for these patients.
Born and raised in Iran, Amouzegar is fluent in Farsi and English. Outside the clinic, she enjoys playing the piano, traveling and spending time with friends and family.
Education & training
Board certification
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Medical Oncology, Univ of Texas MD Anderson Cancer Center
Residency
- Internal Medicine, University of Pittsburgh School of Medicine - GME
Degree
- MD, Tehran University of Medical Sciences
My expertise
Specialties
Locations
My research
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.